3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Neoplasms
1
Metastatic Urothelial Cancer
1
Kidney Neoplasms
1
Kidney Diseases
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Interventions
enfortumab vedotin
4
pembrolizumab
2
Gemcitabine
2
Cisplatin
2
vinflunine
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
sacituzumab govitecan
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
durvalumab
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
avelumab
1
adavosertib
1
X-Rays
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Urinary Bladder Neoplasms
×
avelumab
×
Clear all
NCT02603432
2024-03-27
JAVELIN Bladder 100
Pfizer
Phase 3
Completed
700 enrolled
35 charts
1 FDA